ERBB2 and breast cancer: In the phase Ib DS8201-A-U105 trial, DS-8201 plus nivolumab did not demonstrate a better benefit than DS8201 monotherapy in patients with HER2-positive BC, but the results in the UC cohort were surprising (DCR 76.6%; mPFS 6.9 months; mOS 11.0 months) [110].